Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Eve Kelk"'
Publikováno v:
Life, Vol 11, Iss 2, p 170 (2021)
177Lu-DOTAGA-(l-y)fk(Sub-KuE) a.k.a. 177Lu-PSMA I&T is currently used for radioligand therapy (RLT) of metastatic castration-resistant prostate cancer (mCRPC) in several centers in Europe. Background: Dosimetry is mandatory according to EU guidelines
Externí odkaz:
https://doaj.org/article/362aa81b3b01482ab2c1b76fe61c905c
Publikováno v:
Life, Vol 11, Iss 170, p 170 (2021)
Life
Life
177Lu-DOTAGA-(l-y)fk(Sub-KuE) a.k.a. 177Lu-PSMA I&T is currently used for radioligand therapy (RLT) of metastatic castration-resistant prostate cancer (mCRPC) in several centers in Europe. Background: Dosimetry is mandatory according to EU guidelines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f870a3ff5d71e33a34a9b847c222625b
https://www.mdpi.com/2075-1729/11/2/170
https://www.mdpi.com/2075-1729/11/2/170
Autor:
Kelk, Eve1 (AUTHOR) eve.kelk@itk.ee, Ruuge, Priit2 (AUTHOR) priit.ruuge@itk.ee, Rohtla, Kristi1 (AUTHOR) anne.poksi@itk.ee, Poksi, Anne1 (AUTHOR), Kairemo, Kalevi3 (AUTHOR) kalevi.kairemo@gmail.com, Autelli, Riccardo (AUTHOR)
Publikováno v:
Life (2075-1729). Feb2021, Vol. 11 Issue 2, p170. 1p.
Autor:
Antti, Jekunen
The Evolution of Radionanotargeting towards Clinical Precision Oncology is a remarkable book honoring Professor Kalevi Kairemo, who is known among academic and medical circles as a pioneer in novel radiolabeled therapeutics. This festschrift provides
